Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Leukemia Therapeutics Market to 2018

2236.46

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,236.47

Change Currency

GBP EURO USD
GBP EURO USD

Market

Healthcare and Medical

Report Type

Market Research

Country

Global

Published

1 November 2012

Number of Pages

145

Report Delivery

Email

Delivery Lead Time

1-3 hours, 24 hour max

Publisher

GBI Research

File Format

PDF

Global leukemia therapeutics market to grow to a value of $7.6 billion by 2018

While some areas of the leukemia drugs pipeline are showing promise, the therapeutics market must also focus on reducing the number of people being misdiagnosed as to their particular type and subtype of the disease in order to move forward.

The revenue of the leukemia treatment market has increased at a Compound Annual Growth Rate (CAGR) of 21% during the past eight years, due to the launch of new therapies including Sprycel (dasatinib), Tasigna (nilotinib), Clolar (cloferabine) and Arranon (nelarabine), which will continue to enjoy patent protection throughout the next six years covered by the reports forecast period.

The leukemia therapeutics market last year was dominated by branded drugs such as Gleevec (imatinib), Tasigna, Clolar and Arranon with a market share of 85%, while generics such as vincristine, doxorubicin, methotrexate and cytarabine accounted for the remaining 15% share.

During late 2011, the R&D pipeline for leukemia therapeutics had roughly 1,415 clinical trials in various stages of development, including several late stage first-in-class molecules soon expected to be launched. As Acute Myelogenous Leukemia (AML) therapeutics accounted for 43% of the leukemia drug development pipeline, the report predicts a future improvement on the lack of treatment options and correspondingly high mortality rate associated with this disease at present.

However, the report also notes that the risk of misdiagnosis may be an obstacle for the future development of the leukemia market. As leukemia exists in four different types and 50 subtypes, each having a unique genetic signature and requiring different prognosis and treatment, diagnostic tests for leukemia are expensive and inaccurate, with around 50% of all patients misdiagnosed as per their exact subtype of the disease. While new techniques allow for the analysis of all 400 genes that are known to be causes of leukemia in order to find which corresponds to different subtypes, achieving accurate diagnosis remains a challenge and may prove to be a significant obstacle for the leukemia therapeutics market to overcome.

In 2011, the leukemia therapeutics market for four major leukemia indications was estimated at $4.0 billion, indicating a compound annual growth rate (CAGR) of 21.0% since 2004. We forecast the market to grow at a CAGR of 9.5% between 2011 and 2018 to reach to $7.6 billion by 2018. The four indications covered are treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). The historic growth in major markets such as the US, the top five countries of Europe and Japan were driven mainly by the increasing prevalence and prescription population as well as launch of newer brands such as Sprycel, Tasigna, Clolar and Arranon with no major patent expirations.

The US was the leading market with an estimated sales value of $1.8 billion in 2011 and an approximate share of 44.3%. The US market is expected to grow at a CAGR of 10.0% between 2011 and 2018 to record sales value of $3.5 billion in 2018. The top five countries of Europe together contributed to sales worth $1.5 billion in 2011, accounting for an approximate share of 37.9%. The top five countries of Europe are expected to record sales worth $3.1 billion by the year 2018, at a CAGR of 10.3%. Japan, in 2011, contributed $720m to the global market increasing at a CAGR of 20.8% from 2004. It accounts for an approximate share of 17.8%. Growing at a CAGR of 6.1% between 2011 and 2018, the market is expected to record sales worth $1.1 billion by 2018.

Report Overview

This report provides insights into leukemia therapeutics market until 2018 for four major indications. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

The report provides an in-depth analysis of the major leukemia indications including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelocytic leukemia (AML) and chronic myelocytic leukemia (CML). The report examines the global leukemia diseases treatment usage patterns. In addition, the geographical distribution of leukemia therapeutics and markets across the US, the top five countries of Europe and in Japan are provided in the report. The report also includes insights into the leukemia therapeutics R&D product pipeline and explores the competitive landscape including major players in the leukemia therapeutics market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in leukemia therapeutics market.

Scope

- Data and analysis on the leukemia therapeutics market in the leading geographies of the world – the US, Japan, the UK, Germany, France, Italy and Spain
- Annualized market data for the leukemia therapeutics market from 2004 to 2011, with forecasts to 2018
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the global leukemia therapeutics market including top companies benchmarking. The key companies studied in this report are Novartis AG, GlaxoSmithKline plc (GSK), Genzyme Corporation, Bristol-Myers Squibb Company (BMS) and Eisai Co., Ltd.
- Key M&A activities and licensing agreements that took place in 2009 and 2011 in the leukemia therapeutics market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,236.47

Change Currency

GBP EURO USD

Change Currency

GBP
USD

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings